VRN101099: a novel oral treatment option for patients with advanced solid tumors including brain metastasis driven by HER2 amplification or HER2-activating mutations even with T-DXd resistance

被引：0
|
作者：
Jung, H. R. [1 ]
Ko, Y. [1 ]
Yoo, J. [1 ]
Kim, S. H. [1 ]
Kim, H. [1 ]
Seo, K. [1 ]
Kim, Y. [1 ]
Lee, S. [1 ]
Im, H. [1 ]
Shin, D. [1 ]
Kim, H. [1 ]
Kim, J. [1 ]
Cho, H. Y. [1 ]
Je, S. [1 ]
Kim, D. [1 ]
Kim, S. [1 ]
机构：
[1] Voronoi Inc, R&D Ctr, Incheon, South Korea
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114985
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB-507
引用
收藏
页码：S181 / S181
页数：1
相关论文
共 18 条
  • [1] A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of solid tumors harboring specific HER2-activating mutations (DESTINY-PanTumor01).
    Li, Bob T.
    Meric-Bernstam, Funda
    Puvvada, Soham D.
    Rowbottom, Jacqui
    Jolliffe, Darren
    Gustavson, Mark
    Mendoza-Naranjo, Ariadna
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
    Makker, V.
    Lee, J-Y.
    Oh, D-Y.
    Oaknin, A.
    Puvvada, S. D.
    Cecchi, F.
    Mcewen, R.
    Michelini, F.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S239 - S240
  • [3] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study
    Li, B. T.
    Meric-Bernstam, F.
    Bardia, A.
    Naito, Y.
    Siena, S.
    Aftimos, P. G.
    Anderson, I.
    Curigliano, G.
    De Miguel Luken, M. J.
    Kalra, M.
    Oh, D-Y.
    Park, J. O.
    Postel-Vinay, S.
    Rha, S. Y.
    Satoh, T.
    Spanggaard, I.
    Michelini, F.
    Smith, A.
    Machado, K. Kalil
    Saura Manich, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S459 - S460
  • [4] Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
    Liu, D.
    Arora, K.
    Makker, V.
    Buonocore, D.
    Shen, R.
    Yaeger, R.
    Ginsberg, M. S.
    Yeh, R.
    Offin, M. D.
    Solit, D.
    Drilon, A. E.
    Rudin, C. M.
    Kris, M. G.
    Razavi, P.
    Drago, J.
    Chandarlapaty, S.
    Berger, M.
    Ho, A. L.
    Li, B. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S510 - S510
  • [5] Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases
    Baird, R. D.
    Arkenau, H-T
    Deva, S.
    Cresti, N.
    Garcia-Corbacho, J.
    Hogarth, L.
    Frenkel, E.
    Kawaguchi, K.
    Arimura, A.
    Donaldson, K.
    Posner, J.
    Sarker, D.
    Jodrell, D.
    Plummer, R.
    Spicer, J.
    Italiano, A.
    CANCER RESEARCH, 2016, 76
  • [6] Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases.
    Deva, Sanjeev
    Baird, Richard D.
    Cresti, Nicola
    Garcia-Corbacho, Javier
    Hogarth, Linda
    Frenkel, Eugene P.
    Kawaguchi, Keiko
    Arimura, Akinori
    Donaldson, Kirsteen
    Posner, John
    Sarker, Debashis
    Jodrell, Duncan Ian
    Plummer, Ruth
    Spicer, James F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806)
    Taniguchi, Hiroya
    Yagisawa, Masataka
    Satoh, Taroh
    Kadowaki, Shigenori
    Sunakawa, Yu
    Nishina, Tomohiro
    Komatsu, Yoshito
    Esaki, Taito
    Sakai, Daisuke
    Doi, Ayako
    Kajiwara, Takeshi
    Ono, Hiromi
    Asano, Masatoshi
    Hirano, Nami
    Odegaard, Justin Iver
    Fujii, Satoshi
    Nomura, Shogo
    Sato, Akihiro
    Yoshino, Takayuki
    Nakamura, Yoshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02)
    Meric-Bernstam, Funda
    Anoka, Chiedozie
    Dobrowolska, Anna
    Chaudhry, Anubhavini
    Rowbottom, Jacqui
    Gustavson, Mark
    Puvvada, Soham
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S156 - S156
  • [9] A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02)
    Meric-Bernstam, Funda
    Anoka, Chiedozie
    Dobrowolska, Anna
    Chaudhry, Anubhavini
    Rowbottom, Jacqui
    Gustavson, Mark
    Puvvada, Soham D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [10] Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
    Planchard, D.
    Brahmer, J. R.
    Yang, J. C-H.
    Kim, H. R.
    Li, R. K.
    Han, J-Y.
    Cortinovis, D. L.
    Runglodvatana, Y.
    Nakajima, E.
    Ragone, A.
    Winter, M.
    Gustavson, M.
    ANNALS OF ONCOLOGY, 2023, 34
12